Engineered cells take aim at tough autoimmune diseases
Disease control
Recruiting now
This early-stage study tests a new treatment called CTX112 for people with severe autoimmune diseases like lupus, scleroderma, or myositis that haven't improved with standard therapies. CTX112 uses specially engineered immune cells from a donor to target and attack faulty immune …
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:58 UTC